Alzheimer’s Weekly was selected by HealthLine.com as one of the best Alzheimer’s sites of the year. See what makes Alzheimer’s Weekly stand out from the crowd.
This site was inspired by my Mom’s autoimmune dementia.
It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.
The site is dedicated to all those preserving the dignity of the community of people living with dementia.
Peter Berger, Editor
Share this page To
The newest Alzheimer’s drugs, Kisunla and Leqembi, are the first to actually slow down Alzheimer’s. How do they compare to each other?
Learn about 2025’s newly approved or potential Alzheimer’s drugs. These include Leqembi, Kisunla, Remternetug, Semaglutide, Trontinemab and Bepranemab.
The new Alzheimer’s injections Aduhelm and Lecanemab offer hope. Now, Mastinimab is trying to break through to the next level with a simpler pill. Mastinimab fights Alzheimer’s via a revolutionary mechanism of action. Learn why the FDA approved Mastinimab’s final round of trials.
MEDICATION & MOOD: Aggression and agitation are hard challenges in dementia. An important study may offer some simple answers.
This site was inspired by my Mom’s autoimmune dementia.
It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.
The site is dedicated to all those preserving the dignity of the community of people living with dementia.
Peter Berger, Editor
Visit Alzheimer's Weekly On